Biotech Values

[AlpineBV_Miller]

I think it would be more truthful for you to say that a CU program puts you in an impossible situation.

Geez, Dew, I thought we were past this kind of personal attack stuff on this board.

Let's say for a moment your assertion that DNDN can afford to do a CU program is correct. Ignoring the impact on 9902b for a moment, I would welcome such a program because it would clearly demosntrate the high level of demand for Provenge. Retailers long ago leaned the power of providing samples to test out the market and refine their marketing pitch. A CU program would be exactly that for Dendreon -- one big test marketing exercise.

If we return to reality, it's still a garbage idea because the CU program would rob patients from the 9902b trial. CU programs are limited by resources and the FDA as to how many men can be treated. Delays in completing enrollment would delay when this drug can make it into ALL patients' hands and I don't think that's particularly ethical.